Anamar AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1998-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.anamar.com
Clinical Trials
5
Active:2
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 97
- Registration Number
- NCT04691115
- Locations
- 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: AM1030-CREAM or placebo
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 36
- Registration Number
- NCT02379910
- Locations
- 🇬🇧
Covance CRU, Leeds, United Kingdom
🇬🇧CRLCRU Royal Liverpool University Hospital, Liverpool, United Kingdom
AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- AnaMar AB
- Target Recruit Count
- 40
- Registration Number
- NCT00995605
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
News
No news found